Mesa Laboratories (MLAB) 10-Q 4 Feb 25 2025 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Dec. 31, 2024	Jan. 28, 2025
Document Information [Line Items]
Entity Central Index Key	0000724004
Entity Registrant Name	MESA LABORATORIES INC /CO
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2025
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Dec. 31, 2024
Document Transition Report	false
Entity File Number	0-11740
Entity Incorporation, State or Country Code	CO
Entity Tax Identification Number	84-0872291
Entity Address, Address Line One	12100 West Sixth Avenue
Entity Address, City or Town	Lakewood
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80228
City Area Code	303
Local Phone Number	987-8000
Title of 12(b) Security	Common Stock, no par value
Trading Symbol	MLAB
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,433,607

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Dec. 31, 2024	Mar. 31, 2024
Cash and cash equivalents	$ 30,956	$ 28,214
Accounts receivable, less allowance for credit losses of $1,060 and $1,321, respectively	38,647	39,055
Inventories	28,122	32,675
Prepaid expenses and other current assets	13,120	9,408
Total current assets	110,845	109,352
Noncurrent assets:
Property, plant and equipment, net of accumulated depreciation of $26,036 and $22,519 respectively	31,602	31,766
Deferred tax asset	1,242	1,292
Other assets	18,126	10,538
Intangible assets	98,181	113,752
Goodwill	177,152	180,096
Total assets	437,148	446,796
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable	4,087	6,041
Accrued payroll and benefits	13,919	9,935
Unearned revenues	14,608	15,478
Other accrued expenses	22,351	12,858
Term loan, current portion	3,750	0
Convertible senior notes, current portion, net of debt issuance costs	97,163	0
Total current liabilities	155,878	44,312
Noncurrent liabilities:
Deferred tax liability	18,800	19,780
Other	12,453	15,613
Revolving line of credit	27,000	50,500
Noncurrent portion	67,803	0
Convertible senior notes, noncurrent portion, net of debt issuance costs	0	171,198
Total liabilities	281,934	301,403
Stockholders’ equity:
Common stock, no par value; authorized 25,000,000 shares; issued and outstanding, 5,433,603 and 5,394,491 shares, respectively	352,788	343,642
(Accumulated deficit)	(180,952)	(183,494)
Accumulated other comprehensive (loss)	(16,622)	(14,755)
Total stockholders’ equity	155,214	145,393
Total liabilities and stockholders’ equity	437,148	446,796
Customer Relationships [Member]
Noncurrent assets:
Intangible assets	73,797	85,383
Other Intangible Assets [Member]
Noncurrent assets:
Intangible assets	$ 24,384	$ 28,369

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ / shares in Thousands, $ in Thousands	Dec. 31, 2024	Mar. 31, 2024
Allowance for doubtful accounts receivable	$ 1,060	$ 1,321
Property, plant, and equipment accumulated depreciation	$ 26,036	$ 22,519
Common stock, no par value (in dollars per share)	$ 0	$ 0
Common stock, authorized (in shares)	25,000,000	25,000,000
Common stock, issued (in shares)	5,433,603	5,394,491
Common stock, outstanding (in shares)	5,433,603	5,394,491

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Revenues	[1]	$ 62,840	$ 53,473	$ 178,843	$ 157,283
Cost of revenues		23,086	20,071	66,385	60,589
Gross profit		39,754	33,402	112,458	96,694
Selling		10,450	9,737	30,415	28,363
Research and development		5,053	4,294	14,422	14,098
Total operating expense		33,975	33,469	97,591	97,485
Operating income (loss)		5,779	(67)	14,867	(791)
Interest expense and amortization of debt issuance costs		2,842	1,856	9,340	3,809
Gain on extinguishment of convertible notes		0	0	(2,887)	0
Other expense (income), net		5,154	(3,869)	2,914	(4,284)
Total non-operating expense (income), net		7,996	(2,013)	9,367	(475)
(Loss) earnings before income taxes		(2,217)	1,946	5,500	(316)
Income tax (benefit) expense		(541)	(170)	360	(653)
Net (loss) income		$ (1,676)	$ 2,116	$ 5,140	$ 337
Basic (in dollars per share)		$ (0.31)	$ 0.39	$ 0.95	$ 0.06
Diluted (in dollars per share)		$ (0.31)	$ 0.39	$ 0.94	$ 0.06
Basic (in shares)		5,429	5,393	5,413	5,384
Diluted (in shares)		5,429	5,396	5,464	5,394
Product [Member]
Revenues		$ 62,840	$ 53,473	$ 178,843	$ 157,283
Service [Member]
General and administrative		$ 18,472	$ 19,438	$ 52,754	$ 55,024
[1]Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Net income	$ (1,676)	$ 2,116	$ 5,140	$ 337
Other comprehensive (loss) income:
Foreign currency translation	(6,951)	10,965	(1,867)	2,951
Comprehensive (loss) income	$ (8,627)	$ 13,081	$ 3,273	$ 3,288

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]		Total
Balance at Mar. 31, 2023	$ 332,076	$ 74,199	$ (12,795)	[1]	$ 393,480
Vesting of restricted stock units and exercise of stock options (in shares)	20,074
Vesting of restricted stock units and exercise of stock options	$ 52				52
Tax withholding on vesting of restricted stock units (in shares)	(5,260)
Tax withholding on vesting of restricted stock units	$ (712)	0	0		(712)
Dividends paid, $0.16 per share		(859)			(859)
Stock-based compensation expense	$ 2,968				2,968
Foreign currency translation			(6,661)	[1]	(6,661)
Net income (loss)		(549)			(549)
Balance (in shares) at Jun. 30, 2023	5,384,280
Balance at Jun. 30, 2023	$ 334,384	72,791	(19,456)	[1]	387,719
Balance (in shares) at Mar. 31, 2023	5,369,466
Net income (loss)		(549)			(549)
Foreign currency translation			(6,661)	[1]	(6,661)
Balance at Mar. 31, 2023	$ 332,076	74,199	(12,795)	[1]	393,480
Foreign currency translation					2,951
Net income (loss)					337
Balance (in shares) at Dec. 31, 2023	5,394,043
Balance at Dec. 31, 2023	$ 340,852	71,953	(9,844)	[1]	402,961
Balance (in shares) at Mar. 31, 2023	5,369,466
Net income (loss)					337
Foreign currency translation					2,951
Balance at Jun. 30, 2023	$ 334,384	72,791	(19,456)	[1]	387,719
Vesting of restricted stock units and exercise of stock options (in shares)	7,464
Vesting of restricted stock units and exercise of stock options	$ 304				304
Tax withholding on vesting of restricted stock units (in shares)	(18)
Tax withholding on vesting of restricted stock units	$ (2)				(2)
Dividends paid, $0.16 per share		(862)			(862)
Stock-based compensation expense	$ 3,183				3,183
Foreign currency translation			(1,353)		(1,353)
Net income (loss)		(1,230)			(1,230)
Balance (in shares) at Sep. 30, 2023	5,391,726
Balance at Sep. 30, 2023	$ 337,869	70,699	(20,809)	[1]	387,759
Balance (in shares) at Jun. 30, 2023	5,384,280
Net income (loss)		(1,230)			(1,230)
Foreign currency translation			(1,353)		(1,353)
Vesting of restricted stock units and exercise of stock options (in shares)	2,415
Vesting of restricted stock units and exercise of stock options	$ 2				2
Tax withholding on vesting of restricted stock units (in shares)	(98)
Tax withholding on vesting of restricted stock units	$ (12)				(12)
Dividends paid, $0.16 per share		(862)			(862)
Stock-based compensation expense	$ 2,993				2,993
Foreign currency translation			10,965		10,965
Net income (loss)		2,116			2,116
Balance (in shares) at Dec. 31, 2023	5,394,043
Balance at Dec. 31, 2023	$ 340,852	71,953	(9,844)	[1]	402,961
Balance (in shares) at Sep. 30, 2023	5,391,726
Net income (loss)		2,116			2,116
Foreign currency translation			10,965		$ 10,965
Balance (in shares) at Mar. 31, 2024	5,394,491				5,394,491
Balance at Mar. 31, 2024	$ 343,642	(183,494)	(14,755)	[1]	$ 145,393
Vesting of restricted stock units and exercise of stock options (in shares)	20,858
Vesting of restricted stock units and exercise of stock options	$ 0				0
Tax withholding on vesting of restricted stock units (in shares)	(6,194)
Tax withholding on vesting of restricted stock units	$ (571)	0	0		(571)
Dividends paid, $0.16 per share		(863)			(863)
Stock-based compensation expense	2,928				2,928
Foreign currency translation			452	[1]	452
Net income (loss)	$ 0	3,388	0		3,388
Balance (in shares) at Jun. 30, 2024	5,409,155
Balance at Jun. 30, 2024	$ 345,999	(180,969)	(14,303)	[1]	150,727
Net income (loss)	$ 0	3,388	0		3,388
Foreign currency translation			452	[1]	$ 452
Balance (in shares) at Mar. 31, 2024	5,394,491				5,394,491
Balance at Mar. 31, 2024	$ 343,642	(183,494)	(14,755)	[1]	$ 145,393
Vesting of restricted stock units and exercise of stock options (in shares)					1,000
Foreign currency translation					$ (1,867)
Net income (loss)					5,140
Balance (in shares) at Dec. 31, 2024	5,433,603
Balance at Dec. 31, 2024	$ 352,788	(180,952)	(16,622)	[1]	155,214
Net income (loss)					5,140
Foreign currency translation					(1,867)
Balance at Jun. 30, 2024	$ 345,999	(180,969)	(14,303)	[1]	150,727
Vesting of restricted stock units and exercise of stock options (in shares)	13,006
Vesting of restricted stock units and exercise of stock options	$ 0				0
Tax withholding on vesting of restricted stock units (in shares)	(2,306)
Tax withholding on vesting of restricted stock units	$ (307)				(307)
Dividends paid, $0.16 per share		(866)			(866)
Stock-based compensation expense	3,837				3,837
Foreign currency translation			4,632		4,632
Net income (loss)	$ 0	3,428	0		3,428
Balance (in shares) at Sep. 30, 2024	5,419,855
Balance at Sep. 30, 2024	$ 349,529	(178,407)	(9,671)	[1]	161,451
Balance (in shares) at Jun. 30, 2024	5,409,155
Net income (loss)	$ 0	3,428	0		3,428
Foreign currency translation			4,632		4,632
Vesting of restricted stock units and exercise of stock options (in shares)	13,780
Vesting of restricted stock units and exercise of stock options	$ 23				23
Tax withholding on vesting of restricted stock units (in shares)	(32)
Tax withholding on vesting of restricted stock units	$ (3)				(3)
Dividends paid, $0.16 per share		(869)			(869)
Stock-based compensation expense	3,239				3,239
Foreign currency translation			(6,951)		(6,951)
Net income (loss)	$ 0	(1,676)	0		(1,676)
Balance (in shares) at Dec. 31, 2024	5,433,603
Balance at Dec. 31, 2024	$ 352,788	(180,952)	(16,622)	[1]	155,214
Balance (in shares) at Sep. 30, 2024	5,419,855
Net income (loss)	$ 0	$ (1,676)	0		(1,676)
Foreign currency translation			$ (6,951)		$ (6,951)
[1]Accumulated Other Comprehensive Income (Loss).

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) - $ / shares	3 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023
Dividends paid, per share (in dollars per share)	$ 0.16	$ 0.16	$ 0.16	$ 0.16	$ 0.16	$ 0.16

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities:
Net income	$ 5,140	$ 337
Adjustments to reconcile net income to net cash from operating activities:
Depreciation of property, plant and equipment	4,028	2,899
Amortization of acquisition-related intangibles	13,002	22,380
Stock-based compensation expense	10,004	9,144
Gain on extinguishment of convertible notes	(2,887)	0
Amortization of step-up in inventory basis	1,232	0
Foreign currency adjustments	2,492	(3,128)
Other	3,914	2,206
Cash from changes in operating assets and liabilities:
Accounts receivable, net	91	8,294
Inventories	(539)	217
Prepaid expenses and other assets	(1,445)	(7,841)
Accounts payable	(1,919)	(1,656)
Accrued liabilities and taxes payable	1,879	(124)
Unearned revenues	(849)	(1,478)
Net cash provided by operating activities	34,143	31,250
Cash flows from investing activities:
Acquisitions, net of cash acquired	0	(79,700)
Purchases of property, plant and equipment	(3,492)	(2,032)
Net cash (used in) investing activities	(3,492)	(81,732)
Cash flows from financing activities:
Proceeds from the issuance of debt, net	73,465	71,000
Repayment of debt	(26,313)	(22,000)
Repurchase of convertible debt	(71,560)	0
Dividends paid	(2,598)	(2,583)
Other financing, net	(1,310)	(648)
Net cash (used in) provided by financing activities	(28,316)	45,769
Effect of exchange rate changes on cash and cash equivalents	407	27
Net increase (decrease) in cash and cash equivalents	2,742	(4,686)
Cash and cash equivalents at beginning of period	28,214	32,910
Cash and cash equivalents at end of period	30,956	28,224
Supplemental non-cash activity:
Right of use assets obtained in exchange for lease liabilities	$ 9,596	$ 4,220

Note 1 - Description of Busines

Note 1 - Description of Business and Summary of Significant Accounting Policies	9 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	Note 1 . Description of Business and Summary of Significant Accounting Policies Description of Business In this quarterly report on Form 10 We are a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries. We offer products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. We have manufacturing operations in the United States and Europe, and our products are marketed by our sales personnel in North America, Europe and Asia Pacific, and by independent distributors in these areas and throughout the rest of the world. We prefer markets in which we can establish a strong presence and achieve high gross profit margins. As of December 31, 2024 four ● Sterilization and Disinfection Control ● Clinical Genomics ● Biopharmaceutical Development ● Calibration Solutions Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information. In the opinion of management, such unaudited information includes all adjustments, consisting of normal recurring adjustments necessary for the fair statement of our financial position and results of operations. The results of operations for interim periods are not may not no 10 10 March 31, 2024 Our fiscal year ends on March 31. Prior Period Reclassifications For the nine December 31, 2024, third not three nine December 31, 2024. Risks and Uncertainties The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods. These estimates represent management's judgment about the outcome of future events. The global business environment continues to be impacted by cost pressures, the overall effects of economic uncertainty, and other factors. Changes in, and the resulting effects of, potential governmental stimulus or fiscal and monetary policies, interest rates, foreign currency values, supply chains, demand for goods and services, a global or regional recession, or other circumstances cannot be reliably predicted. Actual results could differ from our estimates. Recently Issued Accounting Pronouncements In November 2023, No. 2023 07, 280 No. 2023 07 280 December 15, 2023 ( 2025 December 15, 2024 ( 2026 not No. 2023 07 In December 2023, No. 2023 09, 740 No. 2023 09, December 15, 2024 ( 2026 not No. 2023 09 In November 2024, No. 2024 03, 220 40 No. 2024 03 December 15, 2026 ( 2028 December 15, 2027 ( 2029 We have reviewed all recently issued accounting pronouncements and have concluded that, other than as described above, they are either not not

Note 2 - Significant Transactio

Note 2 - Significant Transactions	9 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Significant Transactions [Text Block]	Note 2 . Significant Transactions GKE - Fiscal Year 2024 We acquired 100% of the outstanding shares of GKE GmbH and SAL GmbH effective October 16, 2023, December 31, 2023, GKE develops, manufactures and sells a portfolio of chemical sterilization indicators, biologics, and process challenge devices to protect patient safety across global healthcare markets. GKE is included in our Sterilization and Disinfection Control ("SDC") division, and GKE's strengths in chemical indictors are complementary to SDC's strengths in biological indicators as chemical and biological indicators are used in the same sterility validation workflows. Additionally, GKE’s healthcare-focused commercial capabilities in Europe and Asia greatly expand our reach in the healthcare markets in those geographies. We are working to obtain regulatory 510 We finalized our purchase price accounting of GKE during fiscal year 2024. December 31, 2024 April 2025 During the three nine December 31, 2024 Three Months Ended Nine Months Ended December 31, 2024 Revenues $ 6,854 $ 18,971 Gross profit 4,904 12,457 Amortization of inventory step-up recorded in cost of revenues - 1,232 Amortization of acquired intangibles recorded in cost of revenues 131 375 Amortization of acquired intangibles recorded in general and administrative expense 935 2,423

Note 3 - Revenue

Note 3 - Revenue	9 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 3. We develop, manufacture, market, sell and maintain life sciences tools and quality control instruments and related consumables. Hardware sales include physical products such as instruments used for molecular and genetic analysis, protein synthesizers, medical meters, wireless sensor systems, data loggers, and process challenge devices. Hardware sales may Consumables are single-use products and require frequent replacement in our customers' operating cycles. Consumables sold by our Clinical Genomics and Biopharmaceutical Development divisions, such as reagents used for molecular and genetic analysis or solutions used for protein synthesis, are critical to the ongoing use of our instruments. Consumables such as biological and chemical indicator test strips sold by our Sterilization and Disinfection Control division are used on a standalone basis. Revenues from hardware and consumables are recognized upon transfer to the customer, typically at the point of shipment. We also offer maintenance, calibration and testing services. Services result in revenues recognized over time, for example, when we are obligated to perform labor and replace parts on an as-needed basis over a contractually specified period of time, or at a point in time, upon completion of a specific, discrete service. In many cases, our contracts contain both revenues recognized over time and revenues recognized at a point in time. We evaluate our revenues internally based on business division and the nature of goods and services provided. The following tables present disaggregated revenues for the three nine December 31, 2024 2023 Three Months Ended December 31, 2024 Sterilization and Disinfection Control (1) Clinical Genomics Biopharmaceutical Development Calibration Solutions Total Consumables $ 20,991 $ 9,866 $ 4,909 $ 1,043 $ 36,809 Hardware and software 52 1,877 4,534 9,333 15,796 Services 2,464 924 2,794 4,053 10,235 Total revenues $ 23,507 $ 12,667 $ 12,237 $ 14,429 $ 62,840 ( 1 three December 31, 2024 . Three Months Ended December 31, 2023 Sterilization and Disinfection Control (1) Clinical Genomics Biopharmaceutical Development Calibration Solutions Total Consumables $ 16,832 $ 9,758 $ 4,080 $ 539 $ 31,209 Hardware and software 180 1,639 2,672 8,254 12,745 Services 2,326 1,149 2,678 3,366 9,519 Total revenues $ 19,338 $ 12,546 $ 9,430 $ 12,159 $ 53,473 ( 1 three December 31, 2023, October 16, 2023. Nine Months Ended December 31, 2024 Sterilization and Disinfection Control (1) Clinical Genomics Biopharmaceutical Development Calibration Solutions Total Consumables $ 60,860 $ 26,156 $ 12,657 $ 2,067 $ 101,740 Hardware and software 365 6,511 14,539 24,067 45,482 Services 7,444 2,903 8,916 12,358 31,621 Total revenues $ 68,669 $ 35,570 $ 36,112 $ 38,492 $ 178,843 ( 1 nine December 31, 2024 . Nine Months Ended December 31, 2023 Sterilization and Disinfection Control (1) Clinical Genomics Biopharmaceutical Development Calibration Solutions Total Consumables $ 45,288 $ 28,490 $ 12,753 $ 1,834 $ 88,365 Hardware and software 381 9,540 7,838 22,216 39,975 Services 6,676 3,434 7,935 10,898 28,943 Total revenues $ 52,345 $ 41,464 $ 28,526 $ 34,948 $ 157,283 ( 1 nine December 31, 2023, October 16, 2023. Revenues from external customers are attributed to individual countries based upon the locations to which the products are shipped or exported, or locations where services are performed, as follows: Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 United States $ 30,476 $ 25,595 $ 85,415 $ 79,205 China 6,322 4,942 20,271 18,584 Other 26,042 22,936 73,157 59,494 Total revenues $ 62,840 $ 53,473 $ 178,843 $ 157,283 Other than China, no 10% three nine December 31, 2024 2023 Contract Balances Our contracts have varying payment terms and conditions. Some customers prepay for products and services resulting in unearned revenues or customer deposits called contract liabilities. Short-term contract liabilities are included within unearned revenues in the accompanying unaudited Condensed Consolidated Balance Sheets, and long-term contract liabilities are included within other noncurrent liabilities in the accompanying unaudited Condensed Consolidated Balance Sheets. The significant majority of our revenues and related receivables and contract liabilities are generated from contracts with customers with original durations of 12 A summary of contract liabilities is as follows: Contract liabilities as of March 31, 2024 $ 15,686 Prior year liabilities recognized in revenues during the nine months ended December 31, 2024 (9,069 ) Contract liabilities added during the nine months ended December 31, 2024, net of revenues recognized 8,083 Contract liabilities as of December 31, 2024 $ 14,700

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	9 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 4. Our financial instruments consist primarily of cash and cash equivalents, trade accounts receivable, obligations under trade accounts payable, and debt. Due to their short-term nature, the carrying values for cash and cash equivalents, trade accounts receivable, and trade accounts payable approximate fair value; they are classified within Level 1 The financial instruments that subject us to the highest concentration of credit risk are cash and accounts receivable. We maintain relationships and cash deposits at multiple banking institutions across the world in an effort to diversify and reduce risk of loss. Concentration of credit risk with respect to accounts receivable is limited to customers to whom we make significant sales. No 10% December 31, 2024 On April 5, 2024, August 15, 2025 ( 7. December 31, 2024 2 The estimated fair value and carrying value of the Notes were as follows: December 31, 2024 March 31, 2024 Carrying Value Fair Value (Level 2) Carrying Value Fair Value (Level 2) Notes $ 97,163 $ 94,819 $ 171,198 $ 163,013 The carrying amounts of our term loan and revolving line of credit (together, the "Credit Facility") on the unaudited Condensed Consolidated Balance Sheets approximate fair value due to the variable interest rate pricing on the debt, with the balance bearing an interest rate approximating current market rates. We expect to pay approximately $9,000 (at December 31, 2024 April 2025. December 31, 2024 3 During fiscal year 2023, 3 Amounts recognized or disclosed at fair value in the unaudited condensed consolidated financial statements on a nonrecurring basis include the initial recognition and disclosure of most assets and liabilities purchased in business acquisitions and any related measurement period adjustments. Additionally, assets such as property and equipment, operating lease assets, goodwill and other intangible assets are adjusted to fair value if determined to be impaired. Fair values of such assets and liabilities require measurement using Level 3 no three nine December 31, 2024 2023 There were no three nine December 31, 2024

Note 5 - Supplemental Informati

Note 5 - Supplemental Information	9 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	Note 5. Inventories consisted of the following: December 31, 2024 March 31, 2024 Raw materials $ 16,584 $ 18,335 Work in process 400 1,256 Finished goods 11,138 13,084 Total inventories $ 28,122 $ 32,675 Prepaid expenses and other current assets consisted of the following: December 31, 2024 March 31, 2024 Prepaid expenses $ 3,251 $ 2,932 Deposits 1,338 1,898 Prepaid income taxes 5,682 1,237 Other current assets 2,849 3,341 Total prepaid expenses and other current assets $ 13,120 $ 9,408 Accrued payroll and benefits consisted of the following: December 31, 2024 March 31, 2024 Bonus payable $ 7,803 $ 3,838 Wages and paid-time-off payable 3,600 3,072 Payroll related taxes 1,954 1,956 Other benefits payable 562 1,069 Total accrued payroll and benefits $ 13,919 $ 9,935 The increase in bonus payable is primarily due to our financial performance in fiscal year 2025 2024. Other accrued expenses consisted of the following: December 31, 2024 March 31, 2024 Accrued business taxes $ 5,505 $ 5,557 Current operating lease liabilities 3,535 2,986 Income taxes payable 1,364 1,615 Current acquisition-related holdbacks 9,531 436 Other 2,416 2,264 Total other accrued expenses $ 22,351 $ 12,858 The increase in other accrued expenses is primarily due to the reclassification of held back Belyntic and GKE acquisition-related consideration from noncurrent liabilities. Other noncurrent liabilities consisted of the following: December 31, 2024 March 31, 2024 Noncurrent operating lease liabilities $ 12,361 $ 6,613 Noncurrent acquisition-related holdbacks - 8,792 Other 92 208 Total other noncurrent liabilities $ 12,453 $ 15,613 The increase in operating lease liabilities is primarily attributable to the right of use asset associated with an operating lease for a facility used by our Biopharmaceutical Development for manufacturing and administrative purposes. Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Depreciation expense in cost of revenues $ 610 $ 788 $ 2,376 $ 2,117 Depreciation expense in operating expense 496 286 1,652 782 Total depreciation expense $ 1,106 $ 1,074 $ 4,028 $ 2,899 The increase in depreciation expense for the three nine December 31, 2024

Note 6 - Goodwill and Intangibl

Note 6 - Goodwill and Intangible Assets, Net	9 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	Note 6. Finite-lived intangible assets consisted of the following: December 31, 2024 March 31, 2024 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Customer relationships $ 186,272 $ (112,475 ) $ 73,797 $ 189,911 $ (104,528 ) $ 85,383 Other intangibles 60,356 (35,972 ) 24,384 61,161 (32,792 ) 28,369 Total finite-lived intangible assets $ 246,628 $ (148,447 ) $ 98,181 $ 251,072 $ (137,320 ) $ 113,752 Amortization expense for finite-lived intangible assets was as follows: Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Amortization in cost of revenues $ 660 $ 1,883 $ 1,979 $ 5,367 Amortization in general and administrative 3,731 6,092 11,023 17,013 Total amortization expense $ 4,391 $ 7,975 $ 13,002 $ 22,380 The decrease in amortization expense is attributable to impairment losses recorded during the fourth 2024 For the following fiscal years ending March 31, December 31, 2024: Fiscal Year Amortization Expense Remainder of 2025 $ 4,278 2026 16,566 2027 15,921 2028 15,349 2029 14,815 The change in the carrying amount of goodwill was as follows: Sterilization and Disinfection Control Clinical Genomics Biopharmaceutical Development Calibration Solutions Total March 31, 2024 $ 79,430 $ 16,940 $ 46,515 $ 37,211 180,096 Effect of foreign currency translation (1,994 ) (71 ) (849 ) (30 ) (2,944 ) December 31, 2024 $ 77,436 $ 16,869 $ 45,666 $ 37,181 $ 177,152

Note 7 - Indebtedness

Note 7 - Indebtedness	9 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 7 . Indebtedness Credit Facility On March 5, 2021, four 1 2 not 3 not On October 5, 2023, On April 5, 2024, (i) Extend the maturity of the Credit Facility to April 2029; (ii) Allow proceeds from the Credit Facility to be used to redeem some or all of the Company’s 2025 (iii) Include a $75,000 (iv) Make certain changes to the financial covenants. In conjunction with the amendment and restatement of the Credit Facility during the nine December 31, 2024, third Amounts borrowed under the Credit Facility bear interest at either a base rate or a SOFR rate plus an applicable spread ranging from 1.5% to 3.5%, depending on our total net leverage ratio. The weighted average interest rate on borrowings under the Credit Facility as of December 31, 2024 The financial covenants in the Credit Facility as amended include a maximum leverage ratio of 4.50 to 1.00 December 31, 2024; 1.0 March 31, 2025 March 31, 2026; 1.0 1.0 1. December 31, 2024 Term Loan We borrowed $75,000 under the Term Loan on April 5, 2024, three nine December 31, 2024 We are required to make quarterly principal payments on the Term Loan. For the following fiscal years ending March 31, Fiscal Year Amount Remainder of 2025 $ 937 2026 3,750 2027 5,625 2028 5,625 2029 7,500 Thereafter 48,750 Total Principal Remaining $ 72,187 The net carrying amount of the Term Loan was as follows: December 31, 2024 March 31, 2024 Term Loan ( 7.5 $ 72,187 $ - Less: discount and debt issuance costs (634 ) - Less: current portion (3,750 ) - Noncurrent portion $ 67,803 $ - Revolver As of December 31, 2024 December 31, 2024 We are obligated to pay quarterly unused commitment fees of between 0.20% and 0.35% of the Revolver’s aggregate principal amount, based on our leverage ratio. The balance of unamortized customary lender fees related to the Revolver, including fees from the original debt issuance and all subsequent amendments and restatements, was $1,278 and $321 as of December 31, 2024 March 31, 2024, Convert ible Notes On August 12, 2019, August 15, 2025, February 15 August 15 $1,000 On April 5, 2024, nine December 31, 2024. December 31, 2024 Upon conversion, we will pay or deliver, as the case may not three nine December 31, 2024 April 15, 2025 second December 31, 2024 not December 31, 2024 The net carrying amount of the Notes was as follows: December 31, 2024 March 31, 2024 Principal outstanding $ 97,500 $ 172,500 Unamortized debt issuance costs (337 ) (1,302 ) Net carrying value $ 97,163 $ 171,198 We recognized interest expense on the Notes as follows: Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Coupon interest expense at 1.375% $ 335 $ 593 $ 1,037 $ 1,779 Amortization of debt issuance costs 134 231 412 692 Total interest and amortization of debt issuance costs $ 469 $ 824 $ 1,449 $ 2,471 The effective interest rate on the Notes is approximately 1.9%.

Note 8 - Stockholders' Equity

Note 8 - Stockholders' Equity	9 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	Note 8. Stock-Based Compensation During the nine December 31, 2024 2021 The following is a summary of RSU and PSU award activity for the nine December 31, 2024 Time-Based Restricted Stock Units Performance-Based Restricted Stock Units Number of Shares Weighted- Average Grant Date Fair Value per Share Number of Shares Weighted- Average Grant Date Fair Value per Share Outstanding as of March 31, 2024 76 $ 157.83 56 $ 240.96 Awards granted (1) 117 93.46 41 102.57 Awards forfeited (7 ) 123.42 - - Awards distributed (36 ) 169.40 (12 ) 302.06 Outstanding as of December 31, 2024 150 $ 106.44 85 $ 165.75 ( 1 Balances for PSUs granted are reflected at target. Outstanding time-based RSUs vest and settle in shares of our common stock on a one one nine December 31, 2024 third nine December 31, 2024 one We grant PSUs to certain key employees. The number of shares earned is determined at the end of each performance period based on Mesa's achievement of certain pre-defined targets per the related award agreement. The outstanding PSUs vest upon completion of the service period described in the award agreement. We recognize the expense relating to the performance-based RSUs based on the probable outcome of achievement of the performance targets on a straight-line basis over the service period. During the nine December 31, 2024, FY25 April 1, 2024 March 31, 2027. June 18, 2024 June 18, 2027. FY25 June 18, 2024 June 18, 2027. not no The following is a summary of stock option award activity for the nine December 31, 2024 Stock Options Shares Subject to Options Weighted- Average Exercise Price per Share Weighted-Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding as of March 31, 2024 194 $ 181.89 3.2 $ 26 Awards granted - - Awards forfeited or expired (15 ) 150.98 Awards exercised (1 ) 131.67 Outstanding as of December 31, 2024 178 $ 184.55 2.6 $ 287

Note 9 - (Loss) Earnings Per Sh

Note 9 - (Loss) Earnings Per Share	9 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 9 . (Loss) Earnings Per Share The following table presents a reconciliation of the denominators used in the computation of basic and diluted (loss) earnings per share: Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Net (loss) income available for shareholders $ (1,676 ) $ 2,116 $ 5,140 $ 337 Weighted average outstanding shares of common stock 5,429 5,393 5,413 5,384 Dilutive effect of stock options - - - 1 Dilutive effect of RSUs - 3 51 9 Fully diluted shares 5,429 5,396 5,464 5,394 Basic (loss) earnings per share $ (0.31 ) $ 0.39 $ 0.95 $ 0.06 Diluted (loss) earnings per share $ (0.31 ) $ 0.39 $ 0.94 $ 0.06 Potentially dilutive securities include stock options and both time and performance based RSUs (collectively "stock awards"), as well as common shares underlying our Notes. Stock awards are excluded from the calculation of diluted EPS if they are subject to performance conditions that have not not The following potentially dilutive awards were excluded from the calculation of diluted EPS: Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Assumed conversion of the Notes 344 608 354 608 Stock awards that were anti-dilutive 406 277 202 223 Total stock awards excluded from diluted EPS 750 885 556 831 Shares underlying the Notes were excluded from the diluted EPS calculation for the three nine December 31, 2024 2023 nine December 31, 2024 7.

Note 10 - Income Taxes

Note 10 - Income Taxes	9 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 10 . Income Taxes We reported an income tax provision as follows: Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Income tax (benefit) expense $ (541 ) $ (170 ) $ 360 $ (653 ) Effective tax rate 24.4 % (8.7 %) 6.5 % 206.6 % For interim income tax reporting, we estimate our annual effective tax rate and apply this effective tax rate to our year-to-date pre-tax income. Each quarter, our estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. Additionally, the tax effects of significant unusual or infrequently occurring items are recognized as discrete items in the interim period in which the events occur. There is a potential for volatility in the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which they relate, changes in tax laws and foreign tax holidays, settlement with taxing authorities, and foreign currency fluctuations. The change in the effective tax rate for both the three nine December 31, 2024 2024. three nine December 31, 2024 2024.

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	9 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 11 . Commitments and Contingencies We are party to various legal proceedings arising in the ordinary course of business. As of December 31, 2024 not We expect to pay approximately $9,000 (at December 31, 2024 April 2025, may December 31, 2024 As part of the Belyntic acquisition, we agreed to pay the sellers a contingency based upon approval of contractually specified patents. The estimated fair value of the probable remaining contingent consideration was $675 as of December 31, 2024 . January 2, 2025, one two 2025 2026, one December 31, 2024.

Note 12 - Segment Information

Note 12 - Segment Information	9 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 12 . S egment Information The following tables set forth our segment information: Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Revenues (a): Sterilization and Disinfection Control (b) $ 23,507 $ 19,338 $ 68,669 $ 52,345 Clinical Genomics 12,667 12,546 35,570 41,464 Biopharmaceutical Development 12,237 9,430 36,112 28,526 Calibration Solutions 14,429 12,159 38,492 34,948 Total revenues $ 62,840 $ 53,473 $ 178,843 $ 157,283 Gross profit: Sterilization and Disinfection Control (b) $ 16,461 $ 13,951 $ 47,191 $ 38,018 Clinical Genomics 6,948 6,449 19,344 20,904 Biopharmaceutical Development 7,539 5,841 22,665 17,783 Calibration Solutions 8,806 7,212 23,258 20,050 Reportable segment gross profit 39,754 33,453 112,458 96,755 Corporate and other (c) - (51 ) - (61 ) Gross profit $ 39,754 $ 33,402 $ 112,458 $ 96,694 Reconciling items: Operating expense 33,975 33,469 97,591 97,485 Operating income (loss) 5,779 (67 ) 14,867 (791 ) Non-operating expense (income), net 7,996 (2,013 ) 9,367 (475 ) (Loss) earnings before income taxes $ (2,217 ) $ 1,946 $ 5,500 $ (316 ) (a) Intersegment revenues are not (b) Includes post-acquisition GKE results during the three nine December 31, 2024 2023 October 16, 2023 January 1, 2024 (c) Unallocated corporate expenses are reported within corporate and other. The following table sets forth inventories by reportable segment. Our chief operating decision maker is not not December 31, March 31, 2024 2024 Sterilization and Disinfection Control $ 5,728 $ 7,014 Clinical Genomics 10,709 11,813 Biopharmaceutical Development 5,853 6,304 Calibration Solutions 5,832 7,544 Total Inventories $ 28,122 $ 32,675

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2024
Insider Trading Arr Line Items
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Description of Business [Policy Text Block]	Description of Business In this quarterly report on Form 10 We are a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries. We offer products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. We have manufacturing operations in the United States and Europe, and our products are marketed by our sales personnel in North America, Europe and Asia Pacific, and by independent distributors in these areas and throughout the rest of the world. We prefer markets in which we can establish a strong presence and achieve high gross profit margins. As of December 31, 2024 four ● Sterilization and Disinfection Control ● Clinical Genomics ● Biopharmaceutical Development ● Calibration Solutions
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information. In the opinion of management, such unaudited information includes all adjustments, consisting of normal recurring adjustments necessary for the fair statement of our financial position and results of operations. The results of operations for interim periods are not may not no 10 10 March 31, 2024 Our fiscal year ends on March 31.
Reclassification, Comparability Adjustment [Policy Text Block]	Prior Period Reclassifications For the nine December 31, 2024, third not three nine December 31, 2024.
Risk and Uncertainties, Policy [Policy Text Block]	Risks and Uncertainties The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods. These estimates represent management's judgment about the outcome of future events. The global business environment continues to be impacted by cost pressures, the overall effects of economic uncertainty, and other factors. Changes in, and the resulting effects of, potential governmental stimulus or fiscal and monetary policies, interest rates, foreign currency values, supply chains, demand for goods and services, a global or regional recession, or other circumstances cannot be reliably predicted. Actual results could differ from our estimates.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In November 2023, No. 2023 07, 280 No. 2023 07 280 December 15, 2023 ( 2025 December 15, 2024 ( 2026 not No. 2023 07 In December 2023, No. 2023 09, 740 No. 2023 09, December 15, 2024 ( 2026 not No. 2023 09 In November 2024, No. 2024 03, 220 40 No. 2024 03 December 15, 2026 ( 2028 December 15, 2027 ( 2029 We have reviewed all recently issued accounting pronouncements and have concluded that, other than as described above, they are either not not

Note 2 - Significant Transact_2

Note 2 - Significant Transactions (Tables)	9 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	Three Months Ended Nine Months Ended December 31, 2024 Revenues $ 6,854 $ 18,971 Gross profit 4,904 12,457 Amortization of inventory step-up recorded in cost of revenues - 1,232 Amortization of acquired intangibles recorded in cost of revenues 131 375 Amortization of acquired intangibles recorded in general and administrative expense 935 2,423

Note 3 - Revenue (Tables)

Note 3 - Revenue (Tables)	9 Months Ended
	Dec. 31, 2024
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended December 31, 2024 Sterilization and Disinfection Control (1) Clinical Genomics Biopharmaceutical Development Calibration Solutions Total Consumables $ 20,991 $ 9,866 $ 4,909 $ 1,043 $ 36,809 Hardware and software 52 1,877 4,534 9,333 15,796 Services 2,464 924 2,794 4,053 10,235 Total revenues $ 23,507 $ 12,667 $ 12,237 $ 14,429 $ 62,840 Three Months Ended December 31, 2023 Sterilization and Disinfection Control (1) Clinical Genomics Biopharmaceutical Development Calibration Solutions Total Consumables $ 16,832 $ 9,758 $ 4,080 $ 539 $ 31,209 Hardware and software 180 1,639 2,672 8,254 12,745 Services 2,326 1,149 2,678 3,366 9,519 Total revenues $ 19,338 $ 12,546 $ 9,430 $ 12,159 $ 53,473 Nine Months Ended December 31, 2024 Sterilization and Disinfection Control (1) Clinical Genomics Biopharmaceutical Development Calibration Solutions Total Consumables $ 60,860 $ 26,156 $ 12,657 $ 2,067 $ 101,740 Hardware and software 365 6,511 14,539 24,067 45,482 Services 7,444 2,903 8,916 12,358 31,621 Total revenues $ 68,669 $ 35,570 $ 36,112 $ 38,492 $ 178,843 Nine Months Ended December 31, 2023 Sterilization and Disinfection Control (1) Clinical Genomics Biopharmaceutical Development Calibration Solutions Total Consumables $ 45,288 $ 28,490 $ 12,753 $ 1,834 $ 88,365 Hardware and software 381 9,540 7,838 22,216 39,975 Services 6,676 3,434 7,935 10,898 28,943 Total revenues $ 52,345 $ 41,464 $ 28,526 $ 34,948 $ 157,283
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 United States $ 30,476 $ 25,595 $ 85,415 $ 79,205 China 6,322 4,942 20,271 18,584 Other 26,042 22,936 73,157 59,494 Total revenues $ 62,840 $ 53,473 $ 178,843 $ 157,283
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Contract liabilities as of March 31, 2024 $ 15,686 Prior year liabilities recognized in revenues during the nine months ended December 31, 2024 (9,069 ) Contract liabilities added during the nine months ended December 31, 2024, net of revenues recognized 8,083 Contract liabilities as of December 31, 2024 $ 14,700

Note 4 - Fair Value Measureme_2

Note 4 - Fair Value Measurements (Tables)	9 Months Ended
	Dec. 31, 2024
Notes Tables
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	December 31, 2024 March 31, 2024 Carrying Value Fair Value (Level 2) Carrying Value Fair Value (Level 2) Notes $ 97,163 $ 94,819 $ 171,198 $ 163,013

Note 5 - Supplemental Informa_2

Note 5 - Supplemental Information (Tables)	9 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, 2024 March 31, 2024 Raw materials $ 16,584 $ 18,335 Work in process 400 1,256 Finished goods 11,138 13,084 Total inventories $ 28,122 $ 32,675
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	December 31, 2024 March 31, 2024 Prepaid expenses $ 3,251 $ 2,932 Deposits 1,338 1,898 Prepaid income taxes 5,682 1,237 Other current assets 2,849 3,341 Total prepaid expenses and other current assets $ 13,120 $ 9,408
Schedule of Employee Related Liabilities [Table Text Block]	December 31, 2024 March 31, 2024 Bonus payable $ 7,803 $ 3,838 Wages and paid-time-off payable 3,600 3,072 Payroll related taxes 1,954 1,956 Other benefits payable 562 1,069 Total accrued payroll and benefits $ 13,919 $ 9,935
Schedule of Accrued Liabilities [Table Text Block]	December 31, 2024 March 31, 2024 Accrued business taxes $ 5,505 $ 5,557 Current operating lease liabilities 3,535 2,986 Income taxes payable 1,364 1,615 Current acquisition-related holdbacks 9,531 436 Other 2,416 2,264 Total other accrued expenses $ 22,351 $ 12,858
Other Noncurrent Liabilities [Table Text Block]	December 31, 2024 March 31, 2024 Noncurrent operating lease liabilities $ 12,361 $ 6,613 Noncurrent acquisition-related holdbacks - 8,792 Other 92 208 Total other noncurrent liabilities $ 12,453 $ 15,613
Property, Plant and Equipment [Table Text Block]	Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Depreciation expense in cost of revenues $ 610 $ 788 $ 2,376 $ 2,117 Depreciation expense in operating expense 496 286 1,652 782 Total depreciation expense $ 1,106 $ 1,074 $ 4,028 $ 2,899

Note 6 - Goodwill and Intangi_2

Note 6 - Goodwill and Intangible Assets, Net (Tables)	9 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	December 31, 2024 March 31, 2024 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Customer relationships $ 186,272 $ (112,475 ) $ 73,797 $ 189,911 $ (104,528 ) $ 85,383 Other intangibles 60,356 (35,972 ) 24,384 61,161 (32,792 ) 28,369 Total finite-lived intangible assets $ 246,628 $ (148,447 ) $ 98,181 $ 251,072 $ (137,320 ) $ 113,752
Finite-Lived Intangible Assets Amortization Expense [Table Text Block]	Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Amortization in cost of revenues $ 660 $ 1,883 $ 1,979 $ 5,367 Amortization in general and administrative 3,731 6,092 11,023 17,013 Total amortization expense $ 4,391 $ 7,975 $ 13,002 $ 22,380
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Fiscal Year Amortization Expense Remainder of 2025 $ 4,278 2026 16,566 2027 15,921 2028 15,349 2029 14,815
Schedule of Goodwill [Table Text Block]	Sterilization and Disinfection Control Clinical Genomics Biopharmaceutical Development Calibration Solutions Total March 31, 2024 $ 79,430 $ 16,940 $ 46,515 $ 37,211 180,096 Effect of foreign currency translation (1,994 ) (71 ) (849 ) (30 ) (2,944 ) December 31, 2024 $ 77,436 $ 16,869 $ 45,666 $ 37,181 $ 177,152

Note 7 - Indebtedness (Tables)

Note 7 - Indebtedness (Tables)	9 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Maturities of Long-Term Debt [Table Text Block]	Fiscal Year Amount Remainder of 2025 $ 937 2026 3,750 2027 5,625 2028 5,625 2029 7,500 Thereafter 48,750 Total Principal Remaining $ 72,187
Convertible Debt [Table Text Block]	December 31, 2024 March 31, 2024 Principal outstanding $ 97,500 $ 172,500 Unamortized debt issuance costs (337 ) (1,302 ) Net carrying value $ 97,163 $ 171,198
Interest Expense on Convertible Debt [Table Text Block]	Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Coupon interest expense at 1.375% $ 335 $ 593 $ 1,037 $ 1,779 Amortization of debt issuance costs 134 231 412 692 Total interest and amortization of debt issuance costs $ 469 $ 824 $ 1,449 $ 2,471
Term Loan [Member]
Notes Tables
Convertible Debt [Table Text Block]	December 31, 2024 March 31, 2024 Term Loan ( 7.5 $ 72,187 $ - Less: discount and debt issuance costs (634 ) - Less: current portion (3,750 ) - Noncurrent portion $ 67,803 $ -

Note 8 - Stockholders' Equity (

Note 8 - Stockholders' Equity (Tables)	9 Months Ended
	Dec. 31, 2024
Notes Tables
Share-Based Payment Arrangement, Activity [Table Text Block]	Time-Based Restricted Stock Units Performance-Based Restricted Stock Units Number of Shares Weighted- Average Grant Date Fair Value per Share Number of Shares Weighted- Average Grant Date Fair Value per Share Outstanding as of March 31, 2024 76 $ 157.83 56 $ 240.96 Awards granted (1) 117 93.46 41 102.57 Awards forfeited (7 ) 123.42 - - Awards distributed (36 ) 169.40 (12 ) 302.06 Outstanding as of December 31, 2024 150 $ 106.44 85 $ 165.75
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Stock Options Shares Subject to Options Weighted- Average Exercise Price per Share Weighted-Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding as of March 31, 2024 194 $ 181.89 3.2 $ 26 Awards granted - - Awards forfeited or expired (15 ) 150.98 Awards exercised (1 ) 131.67 Outstanding as of December 31, 2024 178 $ 184.55 2.6 $ 287

Note 9 - (Loss) Earnings Per _2

Note 9 - (Loss) Earnings Per Share (Tables)	9 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Net (loss) income available for shareholders $ (1,676 ) $ 2,116 $ 5,140 $ 337 Weighted average outstanding shares of common stock 5,429 5,393 5,413 5,384 Dilutive effect of stock options - - - 1 Dilutive effect of RSUs - 3 51 9 Fully diluted shares 5,429 5,396 5,464 5,394 Basic (loss) earnings per share $ (0.31 ) $ 0.39 $ 0.95 $ 0.06 Diluted (loss) earnings per share $ (0.31 ) $ 0.39 $ 0.94 $ 0.06
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Assumed conversion of the Notes 344 608 354 608 Stock awards that were anti-dilutive 406 277 202 223 Total stock awards excluded from diluted EPS 750 885 556 831

Note 10 - Income Taxes (Tables)

Note 10 - Income Taxes (Tables)	9 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Income tax (benefit) expense $ (541 ) $ (170 ) $ 360 $ (653 ) Effective tax rate 24.4 % (8.7 %) 6.5 % 206.6 %

Note 12 - Segment Information (

Note 12 - Segment Information (Tables)	9 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Revenues (a): Sterilization and Disinfection Control (b) $ 23,507 $ 19,338 $ 68,669 $ 52,345 Clinical Genomics 12,667 12,546 35,570 41,464 Biopharmaceutical Development 12,237 9,430 36,112 28,526 Calibration Solutions 14,429 12,159 38,492 34,948 Total revenues $ 62,840 $ 53,473 $ 178,843 $ 157,283 Gross profit: Sterilization and Disinfection Control (b) $ 16,461 $ 13,951 $ 47,191 $ 38,018 Clinical Genomics 6,948 6,449 19,344 20,904 Biopharmaceutical Development 7,539 5,841 22,665 17,783 Calibration Solutions 8,806 7,212 23,258 20,050 Reportable segment gross profit 39,754 33,453 112,458 96,755 Corporate and other (c) - (51 ) - (61 ) Gross profit $ 39,754 $ 33,402 $ 112,458 $ 96,694 Reconciling items: Operating expense 33,975 33,469 97,591 97,485 Operating income (loss) 5,779 (67 ) 14,867 (791 ) Non-operating expense (income), net 7,996 (2,013 ) 9,367 (475 ) (Loss) earnings before income taxes $ (2,217 ) $ 1,946 $ 5,500 $ (316 )
Schedule of Depreciation and Amortization Expense [Table Text Block]	December 31, March 31, 2024 2024 Sterilization and Disinfection Control $ 5,728 $ 7,014 Clinical Genomics 10,709 11,813 Biopharmaceutical Development 5,853 6,304 Calibration Solutions 5,832 7,544 Total Inventories $ 28,122 $ 32,675

Note 2 - Significant Transact_3

Note 2 - Significant Transactions (Details Textual) - GKE Acquisition [Member] $ in Thousands	Oct. 16, 2023 USD ($)
Payments to Acquire Businesses, Gross	$ 87,187
Business Combination, Consideration Transferred, Liabilities Incurred	9,000
Proceeds from Lines of Credit	$ 71,000
GKE GmbH and SAL GmbH [Member]
Business Acquisition, Percentage of Voting Interests Acquired	100%
Beijing GKE Science & Technology Co. Ltd. [Member]
Business Acquisition, Percentage of Voting Interests Acquired	100%

Note 2 - Significant Transact_4

Note 2 - Significant Transactions - Schedule of Business Acquisitions (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Gross profit	$ 39,754	$ 33,402	$ 112,458	$ 96,694
GKE Acquisition [Member]
Revenues	6,854		18,971
Gross profit	4,904		12,457
GKE Acquisition [Member] | Inventory Step-up Related to Cost of Revenue [Member]
Amortization of inventory step-up recorded in cost of revenues	0		1,232
GKE Acquisition [Member] | Cost of Revenues Related to Intangibles Acquired [Member]
Amortization of inventory step-up recorded in cost of revenues	131		375
GKE Acquisition [Member] | General and Administrative Expense [Member]
Amortization of inventory step-up recorded in cost of revenues	$ 935		$ 2,423

Note 3 - Revenue (Details Textu

Note 3 - Revenue (Details Textual) - USD ($)		3 Months Ended		9 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Revenue from Contract with Customer, Excluding Assessed Tax	[1]	$ 62,840,000	$ 53,473,000	$ 178,843,000	$ 157,283,000
Sterilization and Disinfection Control [Member] | GKE GmbH [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		$ 6,854,000	$ 3,837,000	$ 18,971,000	$ 3,837
[1]Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.

Note 3 - Revenue - Disaggregati

Note 3 - Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands		3 Months Ended			9 Months Ended
		Dec. 31, 2024		Dec. 31, 2023	Dec. 31, 2024		Dec. 31, 2023
Revenue from Contract with Customer, Excluding Assessed Tax	[1]	$ 62,840		$ 53,473	$ 178,843		$ 157,283
Consumables [Member] | Transferred at Point in Time [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		36,809		31,209	101,740		88,365
Hardware and Software [Member] | Transferred at Point in Time [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		15,796		12,745	45,482		39,975
Service [Member] | Transferred at Point in Time [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		10,235		9,519	31,621		28,943
Operating Segments [Member] | Sterilization and Disinfection Control [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	[1],[2]	23,507	[3]	19,338	68,669	[4]	52,345
Operating Segments [Member] | Clinical Genomics [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	[1]	12,667		12,546	35,570		41,464
Operating Segments [Member] | Biopharmaceutical Development [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	[1]	12,237		9,430	36,112		28,526
Operating Segments [Member] | Calibration Solutions [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	[1]	14,429		12,159	38,492		34,948
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		20,991	[3]	16,832	60,860	[4]	45,288
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		9,866		9,758	26,156		28,490
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		4,909		4,080	12,657		12,753
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		1,043		539	2,067		1,834
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		52	[3]	180	365	[4]	381
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		1,877		1,639	6,511		9,540
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		4,534		2,672	14,539		7,838
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		9,333		8,254	24,067		22,216
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		2,464	[3]	2,326	7,444	[4]	6,676
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		924		1,149	2,903		3,434
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		2,794		2,678	8,916		7,935
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		$ 4,053		$ 3,366	$ 12,358		$ 10,898
[1]Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.[2]Includes post-acquisition GKE results during the three and six months ended September 30, 2024.[3]Revenues of $5,863 from GKE are included in the Sterilization and Disinfection Control division during the three months ended September 30, 2024.[4]Revenues of $12,117 from GKE are included in the Sterilization and Disinfection Control division during the six months ended September 30, 2024.

Note 3 - Revenue - Revenues Fro

Note 3 - Revenue - Revenues From External Customers (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Revenue from Contract with Customer, Excluding Assessed Tax	[1]	$ 62,840	$ 53,473	$ 178,843	$ 157,283
UNITED STATES
Revenue from Contract with Customer, Excluding Assessed Tax		30,476	25,595	85,415	79,205
CHINA
Revenue from Contract with Customer, Excluding Assessed Tax		6,322	4,942	20,271	18,584
Other [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		$ 26,042	$ 22,936	$ 73,157	$ 59,494
[1]Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.

Note 3 - Revenue - Contract Lia

Note 3 - Revenue - Contract Liabilities (Details) $ in Thousands	9 Months Ended
	Dec. 31, 2024 USD ($)
Contract liabilities, balance	$ 15,686
Prior year liabilities recognized in revenues during the nine months ended December 31, 2024	(9,069)
Contract liabilities added during the nine months ended December 31, 2024, net of revenues recognized	8,083
Contract liabilities, balance	$ 14,700

Note 4 - Fair Value Measureme_3

Note 4 - Fair Value Measurements (Details Textual) $ in Thousands	3 Months Ended
	Dec. 31, 2024 USD ($)	Apr. 05, 2024 USD ($)	Mar. 31, 2024 USD ($)	Nov. 17, 2022 USD ($)	Aug. 12, 2019
GKE Acquisition [Member]
Business Combination, Hold Back Consideration Liability	$ 9,000
Business Combination, Hold Back Consideration Liability, Fair Value	8,900
GKE Acquisition [Member] | Fair Value, Inputs, Level 3 [Member]
Business Combination, Hold Back Consideration Liability, Fair Value	8,900
Belyntic Acquisition [Member]
Business Combination, Contingent Consideration, Liability Fair Value	675
Belyntic Acquisition [Member] | Other Long-term Liabilities [Member]
Business Combination Contingent Consideration Liability, At Acquisition Date				$ 1,500
Belyntic Acquisition [Member] | Fair Value, Inputs, Level 3 [Member]
Business Combination, Contingent Consideration, Liability Fair Value	675
Outstanding 2025 Notes [Member]
Debt Instrument, Repurchase Amount		$ 75,000
Principal Outstanding	97,500
Senior Notes [Member] | The Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage		1.375%			1.375%
Principal Outstanding	$ 97,500		$ 172,500
Accounts Receivable [Member] | Customer Concentration Risk [Member]
Number of Major Customers	0

Note 4 - Fair Value Measureme_4

Note 4 - Fair Value Measurements - Fair Value and Carrying Value of the Notes (Details) - Senior Notes [Member] - USD ($) $ in Thousands	Dec. 31, 2024	Mar. 31, 2024
Reported Value Measurement [Member]
Notes	$ 97,163	$ 171,198
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]
Notes	$ 94,819	$ 163,013

Note 5 - Supplemental Informa_3

Note 5 - Supplemental Information (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Depreciation	$ 1,106	$ 1,074	$ 4,028	$ 2,899
GKE Acquisition [Member]
Depreciation	$ 225		$ 850

Note 5 - Supplemental Informa_4

Note 5 - Supplemental Information - Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Mar. 31, 2024
Raw materials	$ 16,584	$ 18,335
Work in process	400	1,256
Finished goods	11,138	13,084
Total inventories	$ 28,122	$ 32,675

Note 5 - Supplemental Informa_5

Note 5 - Supplemental Information - Prepaid and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Mar. 31, 2024
Prepaid expenses	$ 3,251	$ 2,932
Deposits	1,338	1,898
Prepaid income taxes	5,682	1,237
Other current assets	2,849	3,341
Total prepaid expenses and other current assets	$ 13,120	$ 9,408

Note 5 - Supplemental Informa_6

Note 5 - Supplemental Information - Accrued Payroll and Benefits (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Mar. 31, 2024
Bonus payable	$ 7,803	$ 3,838
Wages and paid-time-off payable	3,600	3,072
Payroll related taxes	1,954	1,956
Other benefits payable	562	1,069
Total accrued payroll and benefits	$ 13,919	$ 9,935

Note 5 - Supplemental Informa_7

Note 5 - Supplemental Information - Other Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Mar. 31, 2024
Current operating lease liabilities	$ 3,535	$ 2,986
Income taxes payable	1,364	1,615
Current acquisition-related holdbacks	9,531	436
Other	2,416	2,264
Total other accrued expenses	22,351	12,858
Other Accrued Expenses [Member]
Accrued business taxes	$ 5,505	$ 5,557

Note 5 - Supplemental Informa_8

Note 5 - Supplemental Information - Other Noncurrent Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Mar. 31, 2024
Other	$ 12,453	$ 15,613
GKE Acquisition [Member]
Noncurrent operating lease liabilities	12,361	6,613
Noncurrent acquisition-related holdbacks	0	8,792
Other	92	208
Total other noncurrent liabilities	$ 12,453	$ 15,613

Note 5 - Supplemental Informa_9

Note 5 - Supplemental Information - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Depreciation, Total	$ 1,106	$ 1,074	$ 4,028	$ 2,899
Cost of Sales [Member]
Depreciation, Total	610	788	2,376	2,117
Operating Expense [Member]
Depreciation, Total	$ 496	$ 286	$ 1,652	$ 782

Note 6 - Goodwill and Intangi_3

Note 6 - Goodwill and Intangible Assets, Net - Other Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Mar. 31, 2024
Gross carrying amount	$ 246,628	$ 251,072
Accumulated amortization	(148,447)	(137,320)
Net carrying amount	98,181	113,752
Customer Relationships [Member]
Gross carrying amount	186,272	189,911
Accumulated amortization	(112,475)	(104,528)
Net carrying amount	73,797	85,383
Other Intangible Assets [Member]
Gross carrying amount	60,356	61,161
Accumulated amortization	(35,972)	(32,792)
Net carrying amount	$ 24,384	$ 28,369

Note 6 - Goodwill and Intangi_4

Note 6 - Goodwill and Intangible Assets, Net - Amortization Expense for Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Amortization of acquisition-related intangibles	$ 4,391	$ 7,975	$ 13,002	$ 22,380
Cost of Sales [Member]
Amortization of acquisition-related intangibles	660	1,883	1,979	5,367
General and Administrative Expense [Member]
Amortization of acquisition-related intangibles	$ 3,731	$ 6,092	$ 11,023	$ 17,013

Note 6 - Goodwill and Intangi_5

Note 6 - Goodwill and Intangible Assets, Net - Estimated Amortization Expense (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Remainder of 2025	$ 4,278
2026	16,566
2027	15,921
2028	15,349
2029	$ 14,815

Note 6 - Goodwill and Intangi_6

Note 6 - Goodwill and Intangible Assets, Net - Change in the Carrying Amount of Goodwill (Details) $ in Thousands	9 Months Ended
	Dec. 31, 2024 USD ($)
Goodwill	$ 180,096
Effect of foreign currency translation	(2,944)
Goodwill	177,152
Operating Segments [Member] | Sterilization and Disinfection Control [Member]
Goodwill	79,430
Effect of foreign currency translation	(1,994)
Goodwill	77,436
Operating Segments [Member] | Clinical Genomics [Member]
Goodwill	16,940
Effect of foreign currency translation	(71)
Goodwill	16,869
Operating Segments [Member] | Biopharmaceutical Development [Member]
Goodwill	46,515
Effect of foreign currency translation	(849)
Goodwill	45,666
Operating Segments [Member] | Calibration Solutions [Member]
Goodwill	37,211
Effect of foreign currency translation	(30)
Goodwill	$ 37,181

Note 7 - Indebtedness (Details

Note 7 - Indebtedness (Details Textual) $ / shares in Units, $ in Thousands					3 Months Ended			9 Months Ended
	Jan. 01, 2025 USD ($)	Apr. 05, 2024 USD ($)	Mar. 05, 2021 USD ($)	Aug. 12, 2019 USD ($) $ / shares	Dec. 31, 2024 USD ($)	Sep. 30, 2024	Dec. 31, 2023 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Mar. 31, 2024 USD ($)	Oct. 05, 2023 USD ($)
Long-Term Debt					$ 72,187			$ 72,187
Repayments of Debt								26,313	$ 22,000
Gain (Loss) on Extinguishment of Debt					0		$ 0	2,887	$ 0
The Credit Facility Term Loan [Member]
Debt Instrument, Fee Amount					1,987			1,987
Senior Secured Credit Agreement [Member]
Debt Instrument, Term (Year)			4 years
Long-Term Debt					27,000			27,000
Line of Credit Facility, Remaining Borrowing Capacity					98,000			98,000
Senior Secured Credit Agreement [Member] | Prepaid Expenses, Other and Other Assets [Member]
Debt Issuance Costs, Net					1,278			1,278		$ 321
Senior Secured Credit Agreement [Member] | Subsequent Event [Member]
Repayments of Lines of Credit	$ 4,500
Senior Secured Credit Agreement [Member] | The Credit Facility Term Loan [Member]
Debt Instrument, Fee Amount					$ 745			745
Senior Secured Credit Agreement [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate					3.50%
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage						0.35%
Senior Secured Credit Agreement [Member] | Maximum [Member] | The Credit Facility Term Loan [Member]
Line of Credit Facility, Maximum Borrowing Capacity			$ 75,000								$ 125,000
Senior Secured Credit Agreement [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate					1.50%
Fixed Charge Coverage Ratio		1.25
Senior Leverage Ratio		3.5
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage						0.20%
Senior Secured Credit Agreement [Member] | Minimum [Member] | The Credit Facility Term Loan [Member]
Line of Credit Facility, Maximum Borrowing Capacity			25,000
Senior Secured Credit Agreement [Member] | Swingline Loan [Member] | Maximum [Member]
Line of Credit Facility, Maximum Borrowing Capacity			5,000
Senior Secured Credit Agreement [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity			75,000
Debt Instrument, Fee Amount					$ 1,242			$ 1,242
Senior Secured Credit Agreement [Member] | Letter of Credit [Member] | Maximum [Member]
Line of Credit Facility, Maximum Borrowing Capacity			$ 2,500
The Credit Facility Term Loan [Member]
Debt Instrument, Interest Rate, Effective Percentage					7.50%			7.50%
Debt Instrument, Covenant, Maximum Total Leverage Ratio for the First Five Testing Dates		4.5
Debt Instrument, Covenant, Maximum Total Leverage Ratio for the Sixth, Seventh, and Eighth Testing Dates		4
Debt Instrument, Covenant, Maximum Total Leverage Ratio Following the Ninth Testing date		3.5
Term Loan [Member]
Principal Outstanding		$ 75,000			$ 72,187			$ 72,187		0
Debt Instrument, Periodic Payment, Principal					$ 938			$ 2,813
The Notes [Member] | Senior Notes [Member]
Debt Instrument, Interest Rate, Effective Percentage					1.90%			1.90%
Principal Outstanding					$ 97,500			$ 97,500		172,500
Long-Term Debt					97,163			97,163		171,198
Debt Issuance Costs, Net					337			337		$ 1,302
Debt Instrument, Face Amount				$ 172,500
Proceeds from Convertible Debt				$ 167,056
Debt Instrument, Interest Rate, Stated Percentage		1.375%		1.375%
Debt Instrument, Convertible, Conversion Ratio Per 1,000 Principal				3.5273
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares				$ 283.5
Outstanding 2025 Notes [Member]
Principal Outstanding					$ 97,500			97,500
Debt Instrument, Repurchased Face Amount		$ 75,000
Repayments of Debt		71,250
Interest Payable		$ 160
Gain (Loss) on Extinguishment of Debt								$ 2,887

Note 7 - Indebtedness - Quarter

Note 7 - Indebtedness - Quarterly Periodic Payments (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Remainder of 2025	$ 937
2026	3,750
2027	5,625
2028	5,625
2029	7,500
Thereafter	48,750
Total Principal Remaining	$ 72,187

Note 7 - Indebtedness - Carryin

Note 7 - Indebtedness - Carrying Amount of the Term Loan (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Apr. 05, 2024	Mar. 31, 2024
Less: current portion	$ (3,750)		$ 0
Noncurrent portion	67,803		0
Term Loan [Member]
Principal Outstanding	72,187	$ 75,000	0
Less: discount and debt issuance costs	(634)		0
Less: current portion	(3,750)		0
Noncurrent portion	$ 67,803		$ 0

Note 7 - Indebtedness - Carry_2

Note 7 - Indebtedness - Carrying Amount of the Term Loan (Details) (Parentheticals)	9 Months Ended
	Dec. 31, 2024
Term Loan [Member]
Current interest rate	7.50%

Note 7 - Indebtedness - Carry_3

Note 7 - Indebtedness - Carrying Amount of the Notes (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Mar. 31, 2024
Total Principal Remaining	$ 72,187
The Notes [Member] | Senior Notes [Member]
Principal Outstanding	97,500	$ 172,500
Unamortized debt issuance costs	(337)	(1,302)
Total Principal Remaining	$ 97,163	$ 171,198

Note 7 - Indebtedness - Interes

Note 7 - Indebtedness - Interest Expense on the Notes (Details) - The Notes [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Coupon interest expense at 1.375%	$ 335	$ 593	$ 1,037	$ 1,779
Amortization of debt issuance costs	134	231	412	692
Total interest and amortization of debt issuance costs	$ 469	$ 824	$ 1,449	$ 2,471

Note 8 - Stockholders' Equity_2

Note 8 - Stockholders' Equity (Details Textual) - $ / shares shares in Thousands	9 Months Ended
	Dec. 31, 2024	Jun. 30, 2024
Restricted Stock Units (RSUs) [Member] | Non-employee Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	1 year
The FY25 PSUs [Member] | Eligible Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)	41
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized for Service and Company Financial Performance Conditions (in shares)	23
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value, Shares Subject to Service and Company Performance (in dollars per share)	$ 89.82
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized, Subject to Service and Market Conditions (in shares)	18
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value, Subject to Service and Market Conditions (in dollars per share)	$ 119.54
The FY25 PSUs [Member] | Eligible Employees [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award Number of Shares Issued Upon Vesting, Percentage	0%
The FY25 PSUs [Member] | Eligible Employees [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award Number of Shares Issued Upon Vesting, Percentage	200%
The 2021 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)		660

Note 8 - Stockholders' Equity -

Note 8 - Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details)	9 Months Ended
	Dec. 31, 2024 $ / shares shares
Restricted Stock Units (RSUs) [Member]
Awards Outstanding (in shares) | shares	76
Awards Outstanding, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 157.83
Awards granted(1) (in shares) | shares	117	[1]
Awards granted, weighted average grant date fair value per share (1) (in dollars per share) | $ / shares	$ 93.46	[1]
Awards forfeited (in shares) | shares	(7)
Awards forfeited, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 123.42
Awards distributed (in shares) | shares	(36)
Awards distributed, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 169.4
Awards Outstanding (in shares) | shares	150
Awards Outstanding, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 106.44
Performance Stock Units [Member]
Awards Outstanding (in shares) | shares	56
Awards Outstanding, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 240.96
Awards granted(1) (in shares) | shares	41	[1]
Awards granted, weighted average grant date fair value per share (1) (in dollars per share) | $ / shares	$ 102.57	[1]
Awards forfeited (in shares) | shares
Awards forfeited, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 0
Awards distributed (in shares) | shares	(12)
Awards distributed, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 302.06
Awards Outstanding (in shares) | shares	85
Awards Outstanding, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 165.75
[1]Balances for PSUs granted are reflected at target.

Note 8 - Stockholders' Equity_3

Note 8 - Stockholders' Equity - Schedule of Stock Option Award Activity (Details) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended	12 Months Ended
	Dec. 31, 2024 USD ($) $ / shares shares	Mar. 31, 2024 USD ($) $ / shares shares
Options outstanding (in shares) | shares	194
Options outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 181.89
Outstanding, Weighted- Average Remaining Contractual Life (Year)	2 years 7 months 6 days	3 years 2 months 12 days
Outstanding, Aggregate Intrinsic Value | $	$ 287	$ 26
Options granted (in shares) | shares	0
Awards granted, weighted average exercise price (in dollars per share) | $ / shares	$ 0
Options forfeited or expired (in shares) | shares	(15)
Awards forfeited or expired, weighted average exercise price (in dollars per share) | $ / shares	$ 150.98
Awards exercised (in shares) | shares	(1)
Awards exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 131.67
Options outstanding (in shares) | shares	178	194
Options outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 184.55	$ 181.89

Note 9 - Earnings (Loss) Per Sh

Note 9 - Earnings (Loss) Per Share - Computation of Net Income Per Share, Basic & Diluted (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Net income	$ (1,676)	$ 2,116	$ 5,140	$ 337
Weighted average outstanding shares of common stock (in shares)	5,429	5,393	5,413	5,384
Fully diluted shares (in shares)	5,429	5,396	5,464	5,394
Basic (in dollars per share)	$ (0.31)	$ 0.39	$ 0.95	$ 0.06
Diluted (in dollars per share)	$ (0.31)	$ 0.39	$ 0.94	$ 0.06
Share-Based Payment Arrangement, Option [Member]
Dilutive effect of shares (in shares)	0	0	0	1
Restricted Stock Units (RSUs) [Member]
Dilutive effect of shares (in shares)	0	3	51	9

Note 9 - Earnings (Loss) Per _2

Note 9 - Earnings (Loss) Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Total stock awards excluded from diluted EPS (in shares)	750	885	556	831
Assumed Conversion of Convertible Debt [Member]
Total stock awards excluded from diluted EPS (in shares)	344	608	354	608
Stock Awards that were Antidilutive [Member]
Total stock awards excluded from diluted EPS (in shares)	406	277	202	223

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual)	3 Months Ended	9 Months Ended
	Dec. 31, 2024	Dec. 31, 2024
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21%	21%

Note 10 - Income Taxes - Provis

Note 10 - Income Taxes - Provisions for Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Income tax (benefit) expense	$ (541)	$ (170)	$ 360	$ (653)
Effective tax rate	24.40%	(8.70%)	6.50%	206.60%

Note 11 - Commitments and Con_2

Note 11 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	Jan. 02, 2025	Dec. 31, 2024
GKE Acquisition [Member]
Business Combination, Hold Back Consideration Liability		$ 9,000
Business Combination, Hold Back Consideration Liability, Fair Value		8,900
Belyntic Acquisition [Member]
Business Combination, Contingent Consideration, Liability Fair Value		$ 675
Belyntic Acquisition [Member] | Subsequent Event [Member]
Business Combination, Contingent Consideration, Liability, Current	$ 563

Note 12 - Segment Information -

Note 12 - Segment Information - Operating Segment Information (Details) - USD ($) $ in Thousands		3 Months Ended			9 Months Ended
		Dec. 31, 2024		Dec. 31, 2023	Dec. 31, 2024		Dec. 31, 2023
Revenue from Contract with Customer, Excluding Assessed Tax	[1]	$ 62,840		$ 53,473	$ 178,843		$ 157,283
Gross profit		39,754		33,402	112,458		96,694
Operating expense		33,975		33,469	97,591		97,485
Operating income (loss)		5,779		(67)	14,867		(791)
Non-operating expense (income), net		(7,996)		2,013	(9,367)		475
Operating Segments [Member]
Gross profit		39,754		33,453	112,458		96,755
Operating expense		33,975		33,469	97,591		97,485
Operating income (loss)		5,779		(67)	14,867		(791)
Non-operating expense (income), net		7,996		(2,013)	9,367		(475)
(Loss) earnings before income taxes		(2,217)		1,946	5,500		(316)
Operating Segments [Member] | Sterilization and Disinfection Control [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	[1],[2]	23,507	[3]	19,338	68,669	[4]	52,345
Gross profit	[2]	16,461		13,951	47,191		38,018
Operating Segments [Member] | Clinical Genomics [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	[1]	12,667		12,546	35,570		41,464
Gross profit		6,948		6,449	19,344		20,904
Operating Segments [Member] | Biopharmaceutical Development [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	[1]	12,237		9,430	36,112		28,526
Gross profit		7,539		5,841	22,665		17,783
Operating Segments [Member] | Calibration Solutions [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	[1]	14,429		12,159	38,492		34,948
Gross profit		8,806		7,212	23,258		20,050
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]
Gross profit	[5]	$ 0		$ (51)	$ 0		$ (61)
[1]Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.[2]Includes post-acquisition GKE results during the three and six months ended September 30, 2024.[3]Revenues of $5,863 from GKE are included in the Sterilization and Disinfection Control division during the three months ended September 30, 2024.[4]Revenues of $12,117 from GKE are included in the Sterilization and Disinfection Control division during the six months ended September 30, 2024.[5]Unallocated corporate expenses are reported within corporate and other.

Note 12 - Segment Data - Segmen

Note 12 - Segment Data - Segment Depreciation and Amortization (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Mar. 31, 2024
Total inventories	$ 28,122	$ 32,675
Operating Segments [Member] | Sterilization and Disinfection Control [Member]
Total inventories	5,728	7,014
Operating Segments [Member] | Clinical Genomics [Member]
Total inventories	10,709	11,813
Operating Segments [Member] | Biopharmaceutical Development [Member]
Total inventories	5,853	6,304
Operating Segments [Member] | Calibration Solutions [Member]
Total inventories	$ 5,832	$ 7,544